GTx rises on stress urinary incontinence data

GTx Inc. (NASDAQ:GTXI) gained $6.44 (38%) to $23.25 on Monday after reporting data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal selective androgen receptor modulator (SARM).

On the primary endpoint of the single-arm, open-label trial, once-daily 3 mg oral enobosarm reduced the mean number of stress urinary incontinence episodes per day by 81% to 1 leak per day at week 12 from 5.17 leaks per day at baseline. Additionally, all 18 patients had a reduction in stress urinary incontinence episodes per day of at least 50% from baseline...